Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Anteotech Ltd

ADO.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.01

▼ -5.26%

Market Cap $41.65M · Vol 464.54K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$41.65M

Micro Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

N/A

YoY

RSI (14)

45.45

Momentum

Beta

1.32

vs Market

52W High

$0.03

61.66% below

52W Low

$0.01

93.80% above

Volume

464.54K

Avg 7.55M

P/B

7.74

Price-to-book

ROE

N/A

Return on equity

Free Float

86.65%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Anteotech Ltd (ADO.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ADO.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.00%

-14.29%

-41.94%

+50.00%

YTD

-18.18%

-21.74%

-28.35%

-93.63%

Financials & Valuation

TTM · Annual

Total Revenue	$367.25K
Net Income	$-3,409,721.00
Revenue Growth (YoY)	+25.33%
Gross Margin	100.00%
Operating Margin	-1,417.97%
Net Profit Margin	-928.44%
ROE	N/A
ROA · ROIC	-45.12% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	149.92
P/B	7.74
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	3.27B

Technical Indicators

50-Day SMA	$0.01
200-Day SMA	$0.01
RSI (14)	45.45
Beta	1.32
52-Week High	$0.03
52-Week Low	$0.01

Volume Today	464.54K
Avg Daily Volume (30D)	7.55M
Relative Volume	0.06x
Volatility (10D)	101.51
Volatility (30D)	80.64
Free Float	86.65%

Analyst Consensus

N/A

Current Price $0.01

Mean Target N/A

52W Low$0.01 52W High$0.03

Current

Target

$0.01 $0.03

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG001SF2DY5

ISINAU000000ADO8

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +1.23% ONC BeOne Medicines AG +1.55% 068270.KS Celltrion, Inc. +1.75% ABVX Abivax SA +4.66% ABVX.PA Abivax SA +3.59%

Company Profile

AnteoTech Ltd is an Australia-based supplier of advanced material solutions to the battery materials and life sciences markets. Its products and technologies include Anteo X, Ultranode, AnteoBind and AnteoBind NXT. Anteo X is a water-based, binder-compatible cross linker designed to improve the mechanical stability and performance of high silicon anodes in lithium-ion batteries. Anteo X enhances cohesion between active materials, binders, and conductive agents, enabling higher silicon loadings, greater energy density, and improved cycle life. Ultranode is its proprietary high silicon anode formulation technology, developed to boost energy density in lithium-ion batteries. AnteoBind is a patented surface chemistry platform that simplifies and enhances the immobilization (bioconjugation) of biomolecules on a variety of substrates. AnteoBind NXT builds on the core AnteoBind technology, delivering improved binding efficiency, and reducing reagent usage.